PAA Post AGM ,, 2022 Highlights, page-194

Thank you for your post, as one of those negative and yes repetitive posters and if you want to add BODs bashers I needed to respond to a few issues.
I have been in paa since 2012 / 2013 and my reasons for investing back then was that Professor Morris was on the scene, they were taking over PPL from whom they got the rights for monopantel (cancer), David Morris and the research arm of the UNSW had done a lot of studies into what was then called PPL-1.
I back then had the same outlook that it would be good to be invested in a company that from all appears had a good shot at finding a new treatment for human and canine cancers.
Yes the board was very upbeat and confident about the product, even saying if wouldnt take them 10 to 12 years to reformulate the drug and get it to market.
So around 2014 / 2015 and into 2016 there was both human cancer and canine cancer trials carried out, both trials coming back with positive results, but with the drug having adverse affect on patients.
The drug was then turned into a capsule and after a few false starts and adding a masking agent it was claimed there was little to none adverse affects and plans put in place for the human cancer trial to move to a phrase 2 trial, this never progressed as it was decided to wait for data from a phrase 2 canine trial.
A reformulation of the drug was required to turn it into a tablet, during testing of healthy dogs in Cambridge it was found that the best results were obtained at a lower dose of mpl.
Further refining of tablets required.
They had a deal with Elanco, which gave Elanco the first right of refusal, to this end only 6 out of 7 dogs had completed the trial, some still having adverse affects, paa decided that the end points had been met, so sent the data off to Elanco (at the time Elanco were in discussions with another company, who had trialled over a 100 dogs).
PAA claimed to be in regular contact with Elanco but get advised by email that Elanco were not taking up the option (the board stating how surprised they were at the rejection).
Then it is decided that they will get WEHI to test mpl on covid, shows good results, WEHI retest and still comes back with good results, claims made that next step was to push forward with mpl trial and commercialisation, but no then decided to have LAB360 test MPL on covid, again good results but still not good enough so off to Leiden University for more testing, again good results but solubility issues.
Canine cancer trials 2b continues, even after vets recommended moving to phrase 3.
During all this time on a number of occasions paa announced that human cancer trials were up coming and even doing a cr for that purpose.
2021 during current 2b cancer trial it was decided to do a Retrospective analysis of mpl combined standard of care which showed it doubled the life of d5ogs.